Clinical Trial Update: Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS [Phase 2]

View source ↗

Summary

A Phase 2 safety study completed evaluating potential adrenal suppression with maximal use treatment DSXS in psoriasis patients; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• DSXS

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2018-12-06